3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Glioblastoma
21
Brain Neoplasms
15
Central Nervous System Neoplasms
14
Astrocytoma
9
Glioma
7
Oligodendroglioma
5
Medulloblastoma
4
Neoplasms
3
Lymphoma
3
Gliosarcoma
3
Recurrence
2
Melanoma
2
Lymphoma, AIDS-Related
2
Leukemia, Myeloid, Acute
2
Uveal Melanoma
1
Spinal Cord Neoplasms
1
Solid Tumor
1
Optic Nerve Glioma
1
Newly Diagnosed High Grade Glioma
1
Neuroectodermal Tumors
1
Lung Neoplasms
1
Intraocular Lymphoma
1
Familial ependymoma
1
Ependymoma
1
Drug-Related Side Effects and Adverse Reactions
1
Cognition Disorders
1
Carcinoma, Non-Small-Cell Lung
1
Camurati-Engelmann Syndrome
1
Adenocarcinoma, Bronchiolo-Alveolar
1
Adenocarcinoma of Lung
1
Interventions
Cyclophosphamide
12
Whole-Body Irradiation
10
fludarabine phosphate
9
Rituximab
9
Peripheral Blood Stem Cell Transplantation
9
Cyclosporine
9
Mycophenolic Acid
7
Filgrastim
7
Etoposide
6
Dexamethasone
6
Busulfan
6
Methotrexate
5
Tacrolimus
4
Carboplatin
4
Bortezomib
4
Vorinostat
3
Thiotepa
3
Radiotherapy
3
Lenalidomide
3
Irinotecan
3
Cytarabine
3
Calcium Dobesilate
3
merphos
2
liposomal amphotericin B
2
laromustine
2
ixabepilone
2
entinostat
2
Transplantation
2
Therapeutics
2
Prednisone
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Intraocular Lymphoma
×
Lomustine
×
Clear all
NCT00074191
2017-04-21
Protocol-A
OHSU Knight Cancer Institute
Phase 2
Completed
1 enrolled